We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Astellas and Medivation Announce Initiation of Phase 2 Clinical Trial of MDV3100 in Hormone-Naive Prostate Cancer Patients
Product News

Astellas and Medivation Announce Initiation of Phase 2 Clinical Trial of MDV3100 in Hormone-Naive Prostate Cancer Patients

Astellas and Medivation Announce Initiation of Phase 2 Clinical Trial of MDV3100 in Hormone-Naive Prostate Cancer Patients
Product News

Astellas and Medivation Announce Initiation of Phase 2 Clinical Trial of MDV3100 in Hormone-Naive Prostate Cancer Patients


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Astellas and Medivation Announce Initiation of Phase 2 Clinical Trial of MDV3100 in Hormone-Naive Prostate Cancer Patients"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Astellas Pharma Inc. and Medivation, Inc. have announced treatment of the first patient in the second new Phase 2 clinical trial of the investigational drug MDV3100, a triple-acting oral androgen receptor antagonist.

This trial is evaluating MDV3100 monotherapy as the first hormonal treatment of patients with prostate cancer.

Enrolled patients would not have had any previous hormonal therapies for the treatment of prostate cancer. This is the first trial to examine the effects of MDV3100 without a background of medical or surgical castration.

"This is the second of two Phase 2 trials that we and our partner Medivation have initiated this year to evaluate the potential benefit of MDV3100 in both advanced and earlier stage prostate cancer patients," said Steven Ryder, M.D., president, Astellas Pharma Global Development.

"Investigating MDV3100 monotherapy is the next important step to potentially providing a new option for prostate cancer patients with earlier stage disease."

The open-label, single-arm Phase 2 trial is planned to enroll approximately 60 patients in Europe. The primary endpoint of the trial is prostate-specific antigen (PSA) response. The trial will evaluate MDV3100 at a dose of 160 mg taken orally once daily for 24 weeks.

Advertisement